Université Paris-Saclay, Inserm U999, Service de Pneumologie et Soins Intensifs Respiratoires, Hôpital Bicêtre, Assistance Publique Hôpitaux de Paris, Le Kremlin-Bicêtre, France.
Université Paris-Saclay, Inserm U999, Service de Pneumologie et Soins Intensifs Respiratoires, Hôpital Bicêtre, Assistance Publique Hôpitaux de Paris, Le Kremlin-Bicêtre, France.
J Heart Lung Transplant. 2022 Jun;41(6):716-721. doi: 10.1016/j.healun.2022.02.002. Epub 2022 Feb 11.
EXPERT was an international, multicenter, prospective, uncontrolled, non-interventional cohort study in patients with pulmonary hypertension treated with riociguat. Patients were followed for 1-4 years, and the primary outcomes were adverse events (AEs) and serious AEs (SAEs), including embolic/thrombotic and hemorrhagic events. Here we report data on patients with chronic thromboembolic pulmonary hypertension (CTEPH) receiving a vitamin K antagonist (VKA; n = 683) or a non-vitamin K antagonist oral anticoagulant (NOAC; n = 198) at baseline. AEs and SAEs were reported in 438 patients (64.1%) and 257 patients (37.6%), respectively, in the VKA group, and in 135 patients (68.2%) and 74 patients (37.4%) in the NOAC group. Exposure-adjusted hemorrhagic event rates were similar in the two groups, while exposure-adjusted embolic and/or thrombotic event rates were higher in the NOAC group, although the numbers of events were small. Further studies are required to determine the long-term effects of anticoagulation strategies in CTEPH.
EXPERT 是一项国际性、多中心、前瞻性、非干预性、观察性队列研究，纳入了接受 riociguat 治疗的肺动脉高压患者。患者随访 1-4 年，主要结局为不良事件（AE）和严重不良事件（SAE），包括栓塞/血栓形成和出血事件。在此，我们报告了基线时接受维生素 K 拮抗剂（VKA；n=683）或非维生素 K 拮抗剂口服抗凝剂（NOAC；n=198）治疗的慢性血栓栓塞性肺动脉高压（CTEPH）患者的数据。VKA 组中，438 例患者（64.1%）和 257 例患者（37.6%）报告了 AE 和 SAE，NOAC 组中，135 例患者（68.2%）和 74 例患者（37.4%）报告了 AE 和 SAE。两组出血事件的暴露调整发生率相似，而 NOAC 组栓塞和/或血栓形成事件的暴露调整发生率更高，尽管事件数量较少。需要进一步研究来确定抗凝策略在 CTEPH 中的长期影响。
